Circulating irisin in nonalcoholic fatty liver disease: an updated meta-analysis

Qiu, Shanhu1,2,10,11; Wang, Qianqian3,4; Cai, Xue5; Sun, Zilin3,4,8,9; Wu, Tongzhi6,7

2023

10.5603/EP.a2022.0067

Endokrynologia Polska   影响因子和分区

0423-104X

Introduction: Exogenous administration of recombinant irisin may reverse hepatic steatosis and steatohepatitis. However, it remains con-troversial as to whether nonalcoholic fatty liver disease (NAFLD) shows reduced circulating (serum/plasma) irisin levels. A meta-analysis was conducted to address this issue.Material and methods: A literature search of databases was performed up to June 2021. Observational studies that reported circulating irisin in NAFLD ascertained by any methods (e.g. ultrasonography or magnetic resonance) and compared with any controls were eligible for inclu-sion. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were obtained using a random-effects meta-analysis model.Results: Eleven studies enrolling 1277 NAFLD cases and 944 non-NAFLD controls were included. The approaches used for NAFLD as-certainment included ultrasonography (4 studies), magnetic resonance (3 studies), and liver biopsy (5 studies). Meta-analysis showed that circulating irisin in NAFLD was comparable to any non-NAFLD controls (10 studies with 11 datasets; SMD -0.09, 95% CI: -0.48 to 0.29), including the body mass index (BMI)-matched and lean controls (both p >= 0.80). Restricting studies to NAFLD ascertained by magnetic resonance or liver biopsy rather than ultrasonography showed that serum irisin was reduced in NAFLD (5 studies, SMD -0.63, 95% CI: -1.14 to -0.13). Meta-analysis also suggested that circulating irisin did not differ between mild and moderate-to-severe NAFLD (7 studies; SMD 0.02, 95% CI: -0.25 to 0.30), and this association was not significantly moderated by study location (Europe versus Asia). Conclusions: Circulating irisin in NAFLD did not differ from any non-NAFLD controls and was unlikely to be affected by disease severity or racial-ethnic difference. (Endokrynol Pol 2023; 74 (1): 47-54)

irisin nonalcoholic fatty liver disease meta-analysis liver biopsy

SCI

英语

第一 ; 通讯

Guangdong Basic and Applied Basic Research Foundation[2020A1515111021] ; National Natural Science Foundation of China[61844024]

Endocrinology & Metabolism

Endocrinology & Metabolism

WOS:000938166100001

VIA MEDICA

Web of Science

1.Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Dept Endocrinol, Clin Med Coll 2,Jinan Univ,Affiliated Hosp 1, Shenzhen, Peoples R China
2.Southeast Univ, Zhongda Hosp, Res & Educ Ctr Gen Practice, Nanjing, Peoples R China
3.Southeast Univ, Zhongda Hosp, Sch Med, Dept Endocrinol, Nanjing, Peoples R China
4.Southeast Univ, Inst Diabet, Sch Med, Nanjing, Peoples R China
5.Southeast Univ, Zhongda Hosp, Sch Med, Dept Nursing Management, Nanjing, Peoples R China
6.Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia
7.Univ Adelaide, Ctr Res Excellence CRE Translating Nutr Sci Good H, Adelaide, SA, Australia
8.Southeast Univ, Zhongda Hosp, Dept Endocrinol, Nanjing 210009, Peoples R China
9.Southeast Univ, Inst Diabet, Nanjing 210009, Peoples R China
10.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Peoples R China
11.Southeast Univ, Zhongda Hosp, Res & Educ Ctr Gen Practice, Nanjing, Peoples R China

Qiu, Shanhu,Wang, Qianqian,Cai, Xue,et al. Circulating irisin in nonalcoholic fatty liver disease: an updated meta-analysis[J]. Endokrynologia Polska,2023,74(1).

Qiu, Shanhu,Wang, Qianqian,Cai, Xue,Sun, Zilin,&Wu, Tongzhi.(2023).Circulating irisin in nonalcoholic fatty liver disease: an updated meta-analysis.Endokrynologia Polska,74(1).

Qiu, Shanhu,et al."Circulating irisin in nonalcoholic fatty liver disease: an updated meta-analysis".Endokrynologia Polska 74.1(2023).